Senores Pharmaceuticals Ltd (SENORES)
₹1,133.90
Mkt cap
₹5,222 Cr
P/E ratio
39.10
P/B
5.20
Div yield
0.00%
ROE
13.40%
ROCE
15.10%
EPS (TTM)
₹29.00
Book value
₹218
52W range
706–1,599
Sector
Healthcare
Price history
Previous close
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities [1]
NSE SENORESBSE 544319
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−29.09% from high₹1,134
₹706+60.61% from low₹1,599
Current
₹1,133.90
Prev close
₹1,219.20
Day
−7.00%
Price performance
1D
−7.23%
1W
−6.94%
1M
−19.43%
3M
−12.49%
6M
+25.18%
1Y
+51.74%
YTD
+31.04%
Financials
Revenue, profit & margin
P/E ratio
39.1×
SENORES is 15% above the sector median of 34.0×
SENORES39.1×
Sector median34.0×
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 102 | 80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 | 192 | |
| Expenses | 64 | 80 | 59 | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 | 135 | |
| Operating Profit | 15 | 22 | 21 | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 | 58 | |
| OPM % | 19% | 22% | 27% | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% | 30% | |
| Other Income | 1 | 2 | 0 | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 | 9 | |
| Interest | 2 | 3 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 | 9 | |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 | 10 | |
| Profit before tax | 10 | 18 | 13 | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 | 48 | |
| Tax % | 31% | 19% | 19% | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% | 23% | |
| Net Profit | 7 | 14 | 11 | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 | 37 | |
| EPS in Rs | 2.37 | 5.23 | 3.23 | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 | 8.57 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202645.81%Promoter
Promoters45.81%
FIIs6.01%0.61
DIIs10.85%1.08
Public37.32%0.46
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Senores Pharma. | ₹1,133.90 | 39.12 | 5,222 | 0.00% | 37 | +21.96% | 192 | +18.90% | 15.13% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports2
Concall transcripts25
PPTOct 2026RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026PPTDec 2025TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct - Senores Pharmaceuticals Limited has informed regarding Newspaper publication extracts of unaudited financial results for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 29 Oct - Audio recording of Q2 and H1FY27 earnings conference call shared on October 29, 2026.Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants, For The Quarter Ended On September 30, 2026 29 Oct - Senores reported no deviation in use of ₹95.00 crore warrant proceeds for quarter ended September 30, 2026.Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On September 30, 2026 29 Oct - Senores reported no deviation in ₹500 crore IPO use; ₹418.83 crore utilized as of Sept 30, 2026.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 29 Oct - CARE monitoring report for quarter ended September 30, 2026 shows nil deviation and revised IPO utilization.